The document summarizes research into how a furanone compound from marine origins can reduce lipid accumulation in cells in vitro by targeting the LXRα and PPARα nuclear receptors. The study used techniques like fluorescent immunocytochemistry, Western blotting, qPCR, and cell viability assays to examine the compound's effects on receptor expression and activity, as well as lipid levels. Results demonstrated that the furanone enhanced proteins involved in cholesterol efflux like ABCA1 and ABCG1 while increasing LXRα and PPARα expression. This suggests it lowers lipids by influencing multiple metabolic pathways regulated by these receptors. The conclusions discuss the compound's potential natural therapeutic application for hyperlipidemia by modulating the important